News in Numbers

Thermo Fisher is investing $2bn in US manufacturing to counter the effect of the Trump administration’s tariffs.

Abbott’s diabetes business has seen profits rise 27% in Q1 2025.

Retractable Technologies has trimmed its workforce by 7% amid unrest caused by the Trump administration’s tariffs.

The Global Health Innovative Technology (GHIT) Fund has awarded a $4.5m grant to US-based diagnostic developer Fluxus, a Fujirebio subsidiary, to develop an ultrasensitive point-of-care (POC) urine test for tuberculosis (TB).

The UK’s Birmingham University has been awarded $300,000 to develop a multiple myeloma test.